Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
original PI left institute, no plan to continue using samples
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration Lymphocytes (TIL)
The purpose of this study is to allow the collection of tissue from subjects to be used in future research studies by scientists and to isolate tumor fighting cells for the future treatment of Melanoma.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate Feasibility of conducting TIL procurement in a single-site setting | Cell viability, viable number and TIL potency using standardized methods | 5 years |
| Evaluate Safety of conducting TIL procurement in a single-site setting | lab personnel training during procurement, isolation, testing tumor reactivity and cryopreservation | 5 separate TIL procedures |
| Measure | Description | Time Frame |
|---|---|---|
| To determine whether TIL Procurement, isolation, testing tumor reactivity and cryopreservation can be performed at John Wayne Cancer Institute (JWCI) and Providence Saint John's Health Center (PSJHC) and infused into patients | 5 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
cancer clinic
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Santosh Kesari, MD, PhD | Saint John's Cancer Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| John Wayne Cancer Institute | Santa Monica | California | 90404 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | May 9, 2022 | |
| Reset | Feb 7, 2023 | |
| Release | Dec 2, 2024 | |
| Reset | Jan 22, 2025 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| May 9, 2022 | Feb 7, 2023 | |||
| Dec 2, 2024 |
| ID | Term |
|---|---|
| D008545 | Melanoma |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
Tissue from resection of a metastatic melanoma lesion
| Jan 22, 2025 |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |